In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biovail to market Acadia's pimavanserin; terminated

Executive Summary

Acadia Pharmaceuticals (CNS and glaucoma candidates) has granted Biovail's Biovail Laboratories International SRL US and Canadian rights to its Phase III selective 5-HT2A inverse agonist pimavanserin for neurological and psychiatric diseases. Acadia retains rights in all other territories.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • Co-Promotion
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register